In May 2026, despite overall high market valuations, five stocks trading under $30 stand out for their strong financial health and growth prospects. Pfizer offers a 6.68% dividend yield and growth from its non-COVID portfolio and obesity pipeline, while AT&T combines 5G expansion with a 4.5% dividend and strong cash flow. SoFi Technologies shows rapid income growth and debt reduction, though with some risks in loan charge-offs. Kinross Gold provides exposure to gold with strong cash flow and a solid balance sheet amid price volatility. KeyCorp delivers rising margins and capital returns with a 3.89% dividend. Each stock carries risks, but their valuations include a margin of safety for investors willing to do due diligence.
Stocks priced under $30 often get overlooked, but Pfizer and Nu Holdings stand out with solid balance sheets and growth potential. Pfizer, a global biopharma giant, trades around $25 with a strong dividend yield and promising pipeline despite some re...
Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent F...
Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton for their strong cash flow, pricing power, and stable margins amid ongoing inflation. Pfizer offers a 6.66% dividend yield and growth potential as COVID impacts fade, trading at...
